Home > Insider Trading > Filing (0001209191-19-061843)

Filing Details

Accession Number:: 0001209191-19-061843
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-12-23 19:35:17
Reporting Period:: 2019-12-19

Accepted Time:: 2019-12-23 19:35:17
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1714899	Denali Therapeutics Inc.	DNLI	Biological Products, (No Disgnostic Substances) (2836)	463872213

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1724605	Carole Ho	C/O Denali Therapeutics Inc. 161 Oyster Point Blvd. South San Francisco CA 94080	Chief Medical Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2019-12-19	2,566	$20.00	4,324	No	4	S	Direct
Common Stock	Disposition	2019-12-20	860	$20.00	3,464	No	4	S	Direct
Common Stock	Disposition	2019-12-23	3,464	$20.01	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	46,875	Direct
Common Stock	25,000	Indirect	See footnote
Common Stock	79,934	Indirect	See footnote

Footnotes

The shares acquired on August 20, 2019 as reported on the Form 4 filed on August 22, 2019 were incorrectly attributed to the shares held jointly by Carole Ho and Rajat Rohatgi. Column 5 of Table I has been updated to reflect the current balance of shares held by Carole Ho and Rajat Rohatgi, as well as shares held directly in the Reporting Person's sole capacity.
The shares are held of record by Carole Ho and Rajat Rohatgi.
Shares held of record by The Rohatgi-Ho Irrevocable GST Trust, for which Reporting Person serves as trustee.
The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee.
The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares sold ranging from $20.00 to $20.07 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares sold ranging from $20.00 to $20.04 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares sold ranging from $20.00 to $20.08 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.